Understanding Commission Implementing Regulation (EU) 2025/1466 and Pharmacovigilance in 2026 and Beyond

Commission Implementing Regulation (EU) 2025/1466, adopted on 22 July 2025 and implemented on 12 February 2026, marks one of the most significant updates to EU pharmacovigilance (PV) practice since the introduction of Implementing Regulation (EU) No 520/2012.

The new regulation reflects over a decade of practical experience, scientific and technical advances, and the EU’s drive toward international harmonization. This reform affects every Marketing Authorisation Holder (MAH) operating in the European Economic Area (EEA).

Why Regulation 2025/1466 Was Introduced

The update revises Implementing Regulation (EU) No 520/2012, triggered by the need to modernize PV systems in line with:

• Updated scientific understanding
• Technological progress, especially around data and signal management
• International harmonization efforts
• The aim to reduce administrative burden while strengthening oversight

Ultimately, the new regulation seeks to streamline pharmacovigilance, reinforce regulatory oversight, and optimize resource allocation for MAHs.

Major Changes Introduced by Regulation 2025/1466

Pharmacovigilance System Master File (PSMF)

Only open major or critical deviations from PV procedures now need to be documented in the PSMF. This reduces unnecessary administrative activity while keeping focus on issues affecting public health.

Stricter Oversight of Subcontractors

One of the most significant updates is the heightened emphasis on third-party governance:

• Contracts must explicitly set out responsibilities, roles, and data flows
• Subcontractors must permit audits by MAHs and inspections by authorities
• Further subcontracting requires written MAH approval

This change reflects the increasing complexity of outsourced PV operations and aims to ensure oversight regardless of delegation.

Signal Management and EudraVigilance

A structural shift in EU signal processes includes:

• Regulatory authorities now take the lead in continuous, risk-based monitoring of EudraVigilance
• MAHs continue to use EudraVigilance data in signal detection activities
• MAHs no longer validate signals detected in EudraVigilance, ending overlap with regulator processes
• All signals, regardless of source, must follow MAH-defined signal management procedures

Individual Case Safety Reports (ICSRs) and Literature Reporting

ICSRs must meet enhanced completeness expectations:

• Identifiable reporter
• Identifiable patient
• At least one suspected adverse reaction
• Duplicate management processes must be robust

For literature cases:

• DOIs are now required where available
• Vancouver referencing becomes mandatory

Periodic Safety Update Reports (PSURs)

PSURs must now:

• Document both risk minimization measure (RMM) implementation and effectiveness evaluation
• Include expanded safety and benefit-risk information aligned with updated regulatory expectations

Post Authorisation Safety Studies (PASS)

PASS requirements become more digitally driven and transparent:

• Study protocols must be entered into the EU PAS Register before data collection begins
• Final study abstracts must be submitted within 1 month of finalization
• Key milestones must be recorded in the register

Audits and Quality Systems

The regulation reinforces the importance of a risk-based audit program, covering:

• All MAH PV activities
• All subcontracted vendors with PV responsibilities

Global Interoperability Standards

A major step toward international alignment:

• ISO IDMP standards become mandatory
• MedDRA terminology required across all PV submissions

This boosts data quality and facilitates global regulatory collaboration.

Practical Impact on Marketing Authorisation Holders

What MAHs Must Do Now

Many companies face significant operational change, including:

• Conducting full gap analyses
• Updating third-party contracts and governance frameworks
• Upscaling audit activities
• Revising signal management SOPs and templates
• Preparing more detailed PSURs
• Implementing digital requirements for PASS and literature reporting
• Ensuring PSMFs reflect new expectations on deviation recording

Despite the aim to reduce administrative burden, many organisations report an increase in operational complexity, especially around auditing, vendor oversight and risk-based processes.

A Leaner Smarter More Connected EU PV System

Implementing Regulation (EU) 2025/1466 represents a pivotal moment in EU pharmacovigilance evolution. While the regulation reduces routine documentation and eliminates duplicate signal validation, it simultaneously strengthens regulatory accountability, digital transparency, and quality management.

With full implementation required by February 12, 2026, MAHs must act decisively to ensure readiness. Those who proactively upgrade their systems, contracts, and processes will be well positioned to thrive under the more harmonized, data-driven PV framework established by this regulation.

How Navitas Life Sciences Can Support Implementation/h2>

Implementing Commission Implementing Regulation (EU) 2025/1466 requires Marketing Authorisation Holders to reassess their pharmacovigilance systems, vendor governance models, and operational processes. Many organisations are facing challenges in interpreting the updated requirements while maintaining inspection readiness and operational continuity.

Navitas Life Sciences supports MAHs with end-to-end implementation of EU pharmacovigilance regulatory updates, helping organisations transition efficiently to the new regulatory framework.

Our support includes:

• Gap Assessments and Implementation Roadmaps
  Navitas conducts structured gap assessments against Regulation 2025/1466 requirements and develops practical implementation roadmaps to ensure timely compliance while minimizing operational disruption.
• PSMF and Quality System Updates
  Our experts support updates to Pharmacovigilance System Master Files (PSMFs), SOPs, and quality documentation to align with new expectations for deviation tracking and risk-based processes.
• Vendor Governance and Oversight Frameworks
  Navitas helps MAHs strengthen third-party governance by reviewing contracts, defining responsibilities, and establishing robust oversight frameworks that meet regulatory expectations.
• Signal Management Process Alignment
  We support the revision of signal management procedures and workflows to align with the updated EudraVigilance monitoring model and regulator-led signal validation processes.
• Audit Readiness and Risk-Based Audit Programs
  Navitas assists in designing and implementing risk-based pharmacovigilance audit programs covering both internal processes and outsourced vendors.
• PSUR and PASS Compliance Support
  Our teams support preparation of PSURs and PASS documentation aligned with the expanded reporting requirements and EU PAS Register expectations.
• Inspection Readiness and Ongoing Compliance
  Navitas provides ongoing support to maintain inspection readiness through continuous compliance monitoring and quality system improvements.

With deep expertise in EU pharmacovigilance and global regulatory compliance, Navitas helps MAHs navigate the transition to Regulation 2025/1466 with confidence and efficiency.

To explore how Navitas can support your organization, reach out at This email address is being protected from spambots. You need JavaScript enabled to view it..